Will Ozempic Craze Hit Fitness Stocks? Here’s What Analysts Predict.
The surging popularity of weight-loss drugs may immediately seem to be potentially problematic for fitness stocks, as individuals have an alternative to shed pounds, but analysts suggest the craze is likely a boon for the industry as takers of these drugs likely will invest further in their appearance and wellness. Planet Fitness is among the largest gym stocks in the U.S. Shares are down 18% this year. key Katotohanan Soaring sales of injectable GLP-1 semaglutide drugs like Ozempic and Wegovy have boosted the stocks of the drugmakers and weighed on grocery and packaged food stocks reacting negatively to the potential change in Americans diets, but the impact on the fitness sector has been more muted thus far. Though on first thought it may look like the newly unlocked chance to lose weight via medication could dampen interest in gyms, theres a budding consensus on Wall Street that GLP-1s will help, not hurt, the industry; a Morgan Stanley survey last month found a twofold increase in weekly exercise for individuals after beginning their weight-loss drug regimen. BMO Capital Markets analyst Simeon Siegel told he believes Ozempic and similar drugs have “the potential to trigger greater gym usage” as weight loss could lead to a widespread “desire
